Herrmann, Ken
Kratochwil, Clemens
Fendler, Wolfgang P.
Eiber, Matthias
Hustinx, Roland
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
First Online: 22 May 2021
Declarations
:
: Institutional Review Board approval was not required for this Letter to the Editor.
: Not applicable.
: Not applicable.
: The authors are active Nuclear Medicine practitioners and true believers in theranostics. Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics and personal fees from Pharma15, outside the submitted work. Clemens Kratochwil is a co-inventor of the PSMA-617 patent. Wolfgang P. Fendler was a consultant for BTG, and he received fees from RadioMedix, Bayer and Parexel outside of the submitted work. Matthias Eiber reports prior consulting activities for Blue Earth Diagnostics, Progenics Pharmaceuticals and Point Biopharma and a patent application for rhPSMA outside of the submitted work. No further conflicts of interest in regard to this letter to the editor.